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Introduction: Previously, we established a simple method for deriving mesenchymal stem cells (MSCs) from human
induced pluripotent stem cells (iPSC-MSCs). These iPSC-MSCs were capable of forming osteogenic structures in
scaffolds and nanofibers. The objective of this study is to systematically characterize the mesenchymal characteristics
of the iPSC-MSCs by comparing them to bone marrow-derived MSCs (BM-MSCs).
Methods: Two iPSC-MSC lines (named as mRNA-iPSC-MSC-YL001 and lenti-iPSC-MSC-A001) and one BM-MSC line
were used for the study. Cell proliferation, presence of mesenchymal surface markers, tri-lineage differentiation
capability (osteogenesis, chondrogenesis, adipogenesis), and expression of “stemness” genes were analyzed in
these MSC lines.
Results: The iPSC-MSCs were similar to BM-MSCs in terms of cell morphology (fibroblast-like) and surface antigen
profile: CD29+, CD44+, CD73+, CD90+, CD105+, CD11b–, CD14–, CD31–, CD34–, CD45– and HLA-DR–. A faster
proliferative capability was seen in both iPSC-MSCs lines compared to the BM-MSCs. The iPSC-MSCs showed adequate
capacity of osteogenesis and chondrogenesis compared to the BM-MSCs, while less adipogenic potential was found in
the iPSC-MSCs. The iPSC-MSCs and the tri-lineage differentiated cells (osteoblasts, chondrocytes, adipocytes) all lack
expression of “stemness” genes: OCT4, SOX2, GDF3, CRIPTO, UTF1, DPPA4, DNMT3B, LIN28a, and SAL4.
Conclusions: The MSCs derived from human iPSCs with our method have advanced proliferation capability and
adequate osteogenic and chondrogenic properties compared to BM-MSCs. However, the iPSC-MSCs were less efficient
in their adipogenicity, suggesting that further modifications should be applied to our method to derive iPSC-MSCs
more closely resembling the naïve BM-MSCs if necessary.Introduction
Mesenchymal stem cells (MSCs) have been widely used
for tissue engineering due to their unique tri-lineage dif-
ferentiation properties: osteogenesis, chondrogenesis, and
adipogenesis [1, 2]. One attractive application of MSCs for
tissue engineering is to functionalize biomaterials scaffolds* Correspondence: GQZHOU@SZU.EDU.CN; ALUN@BIOMED.AU.DK
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cilitate the replacement and integration of scaffolds into
repairing tissues [3–5]. Currently, adult bone marrow-
derived mesenchymal stem cells (BM-MSC) seem to be
the most reliable cell source for tissue engineering [6].
However, limited proliferating capability of the BM-
MSCs and their replicative senescence after in vitro
expansion hamper their applications in a wide range of
clinical applications [7].
Stem cell-derived MSCs have emerged as a significant al-
ternative cell source to BM-MSCs. Human embryonic stem
cells were mostly used for MSC derivation (ESC-MSCs),is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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logical perspectives have greatly limited the broad use
of ESC-MSCs for clinical interventions. Induced pluri-
potent stem cells (iPSCs) generated from somatic cells
represent a potentially inexhaustible cell resource with
a pluripotent potential similar to ESCs. These iPSCs
have the potential for patient-specific autologous ther-
apies for diseases resulting from injury, genetic predis-
position and/or aging. This approach eliminates most
problems of immune incompatibility and ethical con-
cerns. Since the first report of iPSC generation from
mice and human fibroblasts by retrovirus-mediated re-
programming in 2006 and 2007 [8, 9], several methods
have been established with improved safety and efficacy,
such as protein transduction, mRNA reprogramming, and
transgene free methods with a cocktail of small molecules
[10–12].
Several attempts have been made to derive functional
MSCs from iPSCs (iPSC-MSCs) [13–15]. These iPSC-
MSCs obtain most mesenchymal characteristics of the
naïve BM-MSCs. They are positive for typical mesen-
chymal markers such as CD29 (integrin beta-1), CD73
(ecto-5′-nucleotidase), CD90 (Thy-1), CD105 (endo-
glin), and CD146 (cell surface glycoprotein MUC18).
They lack expression of CD31 (platelet endothelial cell
adhesion molecule-1), CD34 (hematopoietic progenitor
antigen) and CD45 (leukocyte common antigen). Most im-
portantly, these iPSC-MSCs are capable of differentiating
into three functional lineages (osteoblasts, chondrocytes
and adipocytes), and diminish histoincompatibility-
mediated immune responses. Moreover, the iPSC-
MSCs show much greater proliferation and self-renewal
capacity than BM-MSCs, which makes the iPSC-MSCs
a promising substitute for BM-MSCs and ESC-MSCs.
However, safety and efficacy still remain the major chal-
lenges for iPSC-MSCs.
To simplify the MSC generation procedure, we have
previously established a method for iPSC-MSC derivation,
which involves culturing the iPSCs directly in MSC differ-
entiation medium followed by serial trypsinization-based
passaging [16]. We have shown that the iPSC-MSCs
derived by this method obtained a typical mesenchymal
surface marker profile (CD73+, CD90+, CD105+, CD34–,
CD45–) and were capable of osteogenesis in tissue culture
vessels, synthetic three-dimensional and nanofibers. They
also lack tumorigenicity when transplanted into immuno-
deficient mice [4, 16].
Although the iPSC-MSCs derived by our method retain
the mesenchymal functions, their multipotent efficacy as
compared to naïve BM-MSCs is still unknown. To further
characterize the efficacy of iPSC-MSCs derived by our
method, we now compare the proliferative rate, mesen-
chymal marker profile (CD73+, CD90+, CD105+, CD34–,
CD45–), tri-lineage differentiation capacity (osteogenesis,chondrogenesis, and adipogenesis), and pluripotency of
two iPSC-MSC lines and one BM-MSC line.
Methods
Cell culture
Normal human dermal fibroblasts (NHDFs) were kindly
provided by Prof. Thomas G. Jensen from the Department
of Biomedicine, Aarhus University, Aarhus, Denmark.
The use of anonymous NHDFs for basic research is
conducted under the guidelines from the Danish Re-
gional Committee on Health Research Ethics. All stud-
ies were conducted in compliance with the Helsinki
Declaration (http://www.wma.net/en/30publications/10
policies/b3/index.html). NHDF were cultured in D10
medium consisting of Dulbecco’s modified Eagle’s
medium (DMEM), 10 % fetal calf serum, 2 mM L-glutam-
ine, and 1 % penicillin/streptomycin. All ethical approval
and consent was received for the acquisition of these
cells. Human iPSCs were cultured in knockout serum
replacement (KSR) media, consisting of knockout
DMEM (10829–018, Gibco), 20 % Knock Out Serum
Replacement (10828–028, Gibco), 2 mM L-glutamine,
1 % penicillin/streptomycin, 0.1 mM nonessential amino
acids (11140–050, Gibco), 0.1 mM 2-mercaptoethanol
(313-50-010, Gibco) and 10 ng/ml human recombinant
basic fibroblast growth factor (PHG0026, Invitrogen). The
mRNA-iPSCs and mRNA-iPSC-MSC-YL001 were gener-
ated by mRNA transfection and characterized previously
[16]. The human lenti-iPSCs were generated with lenti-
virus transduction using a single polycistronic lentiviral
vector expressing OCT4, SOX2, KLF4 and c-MYC ac-
cording to the methods reported by Papapetrou et al.
[17]. Human BM-MSCs were purchased from Lonza
(PT-2501) and cultured in MSC medium consisting of
DMEM-low glucose (31885–023, Gibco), 10 % fetal
bovine serum (FBS; 26140–079, Gibco), 2 mM L-Glu-
tamine and 1 % penicillin/streptomycin. The K562 cells
were kindly provided by Marianne Hokland from the
Department of Biomedicine, Aarhus University. All cells
were cultured in a tissue culture incubator with 5 % CO2
at 37 °C.
Lentivirus packaging
HEK293 cells were cultured in D10 medium. At the day of
transfection, 1 × 107 HEK293 cells in each P15 dish (nine
dishes in total) were transfected by the CaPO4 co-
precipitation method with pRSV-REV, pMD.2G, pMDGP-
Lg/pRRE plasmids and a lentiviral vector (pLM-fSV2A,
Addgene ID 27512 [18]) expressing the four Yamanaka
factors (OCT4, KLF4, c-Myc and SOX2) polycistronically.
One day after transfection, cells were fed with fresh
medium (17 ml/dish). Cell medium containing lentivirus
was harvested at 48 h and 72 h post-transfection. Lentivirus
was concentrated by ultra-centrifugation (25,000 rpm, 4 °C,
Table 1 List of flow cytometry antibodies
Antibody Catalogue number Dilution
CD11b FITC eBioscience, 11–0113 40×
CD14 V450 BD, 560350 40×
CD29 APC eBioscience, 17–0299 40×
CD31 V450 BD, 561653 40×
CD34 APC BD, 560940 10×
CD44 Cy5.5 BD, 560531 40×
CD45 V450 BD, 560368 40×
CD73 PE BD, 561014 10×
CD90 FITC BD, 555595 50×
CD105 Cy5.5 BD, 560819 40×
HLA-DR Cy5.5 BD, 560652 40×
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with phosphate-buffered saline (PBS) and stored at −80 °C.
Virus titer was measured with the P24 Elisa kit (XB-1000,
XpressBio).
Lentivirus-mediated reprogramming
NHDFs (1.5 × 105 cells/per well) were seeded in a six-
well plate 1 day before transduction. Cells were trans-
duced with reprogramming lentivirus in the presence of
polybrene (8 μg/mL) in D10 medium. Cell media were
changed every other day. Six days post-transduction,
transduced NHDFs (2 × 104 cells/per well) were har-
vested by trypsinization and seeded on irradiation-
inactivated mouse feeder cells in six-well plates, and
cultured in KSR medium. KSR medium was changed
daily. Approximately 21 days post-transduction, the
iPSC colonies were ready for picking and expansion.
Immunofluorescence staining
For immunofluorescence staining, cells were fixed in
4 % paraformaldehyde for 20 min, followed by PBS wash
(three times, 5 min each) and permeabilization with
0.3 % Triton X-100 in PBS for 10 min. The cells were
then blocked with blocking solution (5 % donkey serum
in PBS) at room temperature for 30 min and incubated
with the primary antibodies overnight at 4 °C. Goat anti-
human OCT3/4 (Abcam, ab27985, 100× diluted) and
rabbit antihuman Nanog (Abcam, ab80892, 100× diluted)
were used. Cells were then stained with a secondary anti-
body for 2 h. Alexa 594 donkey anti-goat IgG (H + L) and
Alexa Fluor® 488 Donkey Anti-Rabbit IgG (H + L) (Life
Technologies) were used for second antibody staining. For
live cell staining of TRA-1-60 and CD44, cells were
stained using the live cell imaging kit from Life Technolo-
gies (Tra-1-60 AF594, CD44 AF488) according to the
manufacturer’s protocol. All images were taken with a
Leica fluorescence microscope.
Derivation of MSCs from iPSCs generated by lentiviral
reprogramming
The iPSC-MSC derivation was performed according to
our previous protocol. One characterized pluripotent
lenti-iPSC line was used for MSC differentiation. Briefly,
3 days after passaging the lenti-iPSCs to feeder cell cul-
ture, the KSR medium was replaced with MSC medium.
The lenti-iPSCs were maintained in MSC medium for
2 weeks, with medium changed every other day. Subse-
quently, cells were passaged to gelatin-coated (0.1 % gel-
atin, room temperature for 2 h) tissue culture vessels by
trypsinization (0.25 % trypsin/1 mM EDTA). Cells were
defined as passage 1 (P1) after the first passaging. For
maintenance of iPSC-MSCs, cells were passaged when
90 % confluent and seeded with a density of 1.6 × 104
cells/cm2 to new tissue culture vessels.MSC surface marker characterization by flow cytometry
Detail information on antibodies against the human an-
tigens CD11b, CD14, CD29, CD31, CD34, CD44, CD45,
CD73, CD90, CD105 and HLA-DR are shown in Table 1.
Cells were harvested by trypsinization and washed with
2 % FBS-PBS twice; 2 × 105 cells were re-suspended in
100 μl 2 % FBS-PBS and incubated with the conjugated
antibody for 30 min at room temperature in the dark.
Stained cells were then washed with 2 % FBS-PBS twice
and re-suspended in 500 μl 1 % formaldehyde-PBS for
flow cytometry analysis (LSRFortessa); 10,000 events
were recorded for each sample and data were analyzed
with Flowjo.
Number of population doublings
BM-MSCs, mRNA-iPSC-MSC-YL001 and lenti-iPSC-
MSC-A001 were serially subcultured in six-well plates for
2 weeks. Briefly, cells were cultured in six-well plates;
when cells were 90 % confluent, they were trypsinized and
counted with a hemocytometer. The cells were then
cultured in a new six-well plate with the same starting cell
density. The number of population doublings (NPD) was
calculated according to the following equation: NPD =
log10 (Nh/Ni) × 3.33, where Nh and Ni are the numbers
of harvested and initiating cells, respectively [19]. NPDs
were performed in six replicates for each type of MSC.
Cell proliferation rate assay
Cell proliferation rate measurements were conducted
using the Click-iT® EdU Alexa Fluor® 488 Flow Cytome-
try Assay Kit (Cat. no. C10425, Life Technologies).
K562, BM-MSCs, mRNA-iPSC-MSC-YL001, and lenti-
iPSC-MSC-A001 cells were seeded in six-well plates
(1.0 × 105 cells/well) 24 h prior to changing to fresh
growth medium (negative control) or growth medium
containing 10 μM EdU. Cells cultured in growth
medium without EdU were used as negative controls.
Cells were incubated at 37 °C in a humidified incubator
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and subjected to EdU staining according to the manufac-
turer’s protocol. Briefly, cells were washed with 500 μL
1 % bovine serum albumin (BSA)-PBS, incubated with
100 μL Click-iT fixative for 15 min in the dark, washed
with 500 μL 1 % BSA-PBS, re-suspended with 100 μL
1× component E, stained in labeling cocktail for 30 min,
washed with 500 μL 1× component E, and analyzed by
flow cytometry (LSRFortessa); 10,000 events were re-
corded for each sample and data were analyzed with
Flowjo.Tri-lineage differentiation
BM-MSCs, mRNA-iPSC-MSC-YL001, and lenti-iPS-MSC-
A001 cells (all P9) were used for the tri-lineage differenti-
ation (osteogenesis, chondrogenesis and adipogenesis).
For osteogenic differentiation, cells were seeded at a
density of 1.2 × 104 cells/cm2 in 96-well tissue culture
plates. After 3 days, the media were changed to either
MSC growth medium (as control) or osteogenic differ-
entiation medium, which contains DMEM-high glucose
(Invitrogen), 10 % FBS (Gibco), 1 % penicillin/strepto-
mycin, 100 nM dexamethasone (D2915, Sigma), 10 mM
β-Glycerophosphate (G9891, Sigma), 50 μM ascorbic
acid-2 phosphate (A8960, Sigma), and 10 μM Vit-D
(D1530, Sigma). Cells were maintained in growth medium
or osteogenic differentiation medium for 3 weeks with
medium changed every 3 days. At the end of differenti-
ation, samples were subjected to Alizarin Red S (Sigma)
staining, calcium quantification analysis following the man-
ufacturer’s instructions, and quantitative PCR analysis.
For chondrogenic differentiation, 2.5 × 105 cells were
centrifuged at 500 g for 10 min to form a small pellet in a
“V” shape 96-well plate. The cell pellets were cultured in
either MSC growth medium (as control) or chondrogenic
differentiation medium consisting of DMEM (F12, Gibco)
supplemented with 10 % FBS, 50 μg/mL ascorbic acid,
100 nM dexamethasone, 1:100 ITS premix (BD Biosci-
ences), 40 μg/ml L-proline (Sigma-Aldrich), 10 ng/mL
human recombinant TGF-β3 (R&D systems), and 1 %
penicillin/streptomycin [16, 20]. The medium was chan-
ged every 3 days. After 3 weeks, cell pellets were collected
for toluidine blue staining to validate the extracellular
chondrocyte matrix [21]. Purple stain of proteoglycans
was observed by phase-contrast microscopy.
Adipogenic differentiation was carried out by culturing
the cells at a density of 1.2 × 104 cells/cm2 in DMEM-
high glucose (Invitrogen) supplemented with 15 % horse
serum (Sigma), and 100 nM dexamethasone (Sigma),
1 % penicillin/streptomycin (MSC growth medium as
control). After 3 weeks, cells were stained with Oil-red
O (Sigma-Aldrich) solution to evaluate differentiation
using standard techniques as previously described [22].PCR and quantitative PCR
Total RNA was extracted with an RNeasy Plus Mini Kit
(Qiagen) according to the manufacturer’s instructions,
followed by quantification with a Nanodrop spectro-
photometer and qualification by 1 % agarose gel elec-
trophoresis. First-strand cDNA was synthesized with
approximately 50 ng of total RNA using a cDNA
synthesis kit (170–8891, Bio-Rad). PCR primers for
stemness genes and osteogenic genes are listed in
Table 2.
For PCR characterization of the expression of stemness
genes (OCT4, KLF4, C-MYC, SOX2, GDF3, CRIPTO,
UTF1, DPPA4, DNMT3B, LIN28A and SALL4), PCR was
performed with pfx DNA Polymerase (11708–039,
Invitrogen) using 2 μl (five times diluted) cDNA as DNA
temperate. The following PCR program was optimized for
each stemness gene: 1 cycle of 94 °C for 3 min; 30 cycles
of 94 °C for 30 seconds, 60 °C or 58 °C or 53 °C (see
Table 2) for 30 seconds, and 68 °C for 30 seconds; 1 cycle
at 68 °C for 7 min. The GAPDH gene was used as an
endogenous control.
For quantitative PCR of osteogenic genes (of runt-
related transcription factor 2 (RUNX2), alkaline phos-
phatase (ALP), collagen type I alpha 1 (COL1A1), and
osteocalcin (OC)), 2 uL (five times diluted) cDNA was
used. Quantitative PCR was performed using the Light-
Cycle 480 SYBR Green I Master kit on LightCycler 480
(Roche) with the following PCR program: 1 hold at 95 °
C for 5 min; 50 cycles at 95 °C for 10 seconds, 60 °C
for 10 seconds, and 72 °C for 15 seconds. To mask the
signal from primer dimers, fluorescent signal was mea-
sured at 77 °C for RUNX2, 80 °C for ALP, 82 °C for
GAPDH and COL1A1, and 84 °C for OC. Relative gene
expression was calculated using the 2-ΔΔct method after
normalization to the reference gene GAPDH.
Statistics
All values are reported as mean ± SD. Data were checked
for normal distribution using QQ-plots. The osteogenic
gene expression between growth and osteogenic media
were compared by t-test in each cell line. Quantitative
calcium deposition was investigated using two-way ana-
lysis of variance (media type × cell line). If interactions
were observed, the variables were investigated separately
by the Scheffe method. P < 0.05 was considered statisti-
cally significant.
Results
MSCs from iPSCs induced by lentiviral-mediated
reprogramming have the same fibroblast-like morphology
as BM-MSCs
The procedure for iPSC-MSC derivation, which we had
established previously, was based on an iPSC line estab-
lished by mRNA reprogramming from human fibroblasts
Table 2 List of primers
Gene Primer sequences (5′–3′) Annealing temperature (°C) Amplicon (bp)
OCT4-F CCTCACTTCACTGCACTGTA 58 163
OCT4-R CAGGTTTTCTTTCCCTAGCT
KLF4-F GATGAACTGACCAGGCACTA 60 144
KLF4-R GTGGGTCATATCCACTGTCT
C-MYC-F TGCCTCAAATTGGACTTTGG 58 191
C-MYC-R GATTGAAATTCTGTGTAACTGC
SOX2-F CCCAGCAGACTTCACATGT 58 150
SOX2-R CCTCCCATTTCCCTCGTTTT
GDF3-F AAATGTTTGTGTTGCGGTCA 53 178
GDF3-R TCTGGCACAGGTGTCTTCAG
CRIPTO-F CGGAACTGTGAGCACGATGT 58 65
CRIPTO-R GGGCAGCCAGGTGTCATG
UTF1-F CCGTCGCTGAACACCGCCCTGCTG 58 179
UTF1-R CGCGCTGCCCAGAATGAAGCCCAC
DPPA4-F GGAGCCGCCTGCCCTGGAAAATTC 53 407
DPPA4-R TTTTTCCTGATATTCTATTCCCAT
DNMT3B-F TGCTGCTCACAGGGCCCGATACTTC 58 170
DNMT3B-R TCCTTTCGAGCTCAGTGCACCACAAAAC
LIN28-F AGTAAGCTGCACATGGAAGG 58 420
LIN28-R ATTGTGGCTCAATTCTGTGC
SALL4-F GCCGTGAAGACCAATGAGAT 58 243
SALL4-R CTCCTTCCACGCAAGTTCTC
RUNX2-F CAGTAGATGGACCTCGGGAA 60 188
RUNX2-R CCTAAATCACTGAGGCGGTC
ALP-F ATCAGGGACATTGACGTGATC 60 137
ALP-R TTCCAGGTGTCAACGAGGTC
COL1A1-F AGGGCCAAGACGAAGACATC 60 138
COL1A1-R AGATCACGTCATCGCACAAC
OC-F AGTCCAGCAAAGGTGCAGCC 60 169
OC-R TCAGCCAACTCGTCACAGTC
GAPDH-F TGGTATCGTGGAAGGACTCATGAC 53 189
GAPDH -R ATGCCAGTGAGCTTCCCGTTCAGC
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plied to derive functional MSCs from iPSC lines generated
by other methods. Lentiviral-mediated reprogramming is
favored for its high reprogramming efficiency relative to
other methods [17]. We firstly generated one iPSC line
using lentiviral-mediated reprogramming. The iPSC line
exhibited typical stem cell morphology; expressed pluripo-
tent cell cells markers: TRA1-60 (podocalyxin), OCT4
(octamer-binding transcription factor 4, also known as
POU domain, class 5, transcription factor 1), and
NANOG (Nanog homeobox) (Fig. 1a); lacked expression
of CD44 (the absence of which is crucial for iPSC pluripo-
tency (Fig. 1a)) [23]; and retained normal polyploidy(diploid as fibroblasts, Fig. 1b). We differentiated the iPSC
colony into MSCs using our preciously established pro-
cedure [16]. The MSCs derived from lentivial reprogram-
ming iPSCs (lenti-iPSC-MSCs-A001) had the same
morphology (fibroblast-like) as the BM-MSCs and the
mRNA-iPSC-MSC-YL001 line reported previously [16]
(Fig. 1c), and are karyotypically normal (Fig. 1d).
The iPSC-MSCs obtained similar mesenchymal surface
marker profiles to BM-MSCs through in vitro cultivation
To verify whether the iPSC-MSCs harbor mesenchymal
characteristics, we analyzed the expression of five MSC-
positive surface markers—CD29 (Integrin beta-1), CD44
Fig. 1 Derivation of iPSC-MSCs from iPSCs produced by lentiviral-mediated programming of normal human dermal fibroblasts. a One lenti-iPSC
line characterized by live cell imaging of TRA-1-60+ and CD44–; immunofluorescence staining of NANOG+ and OCT3/4+, and phase-contrast
image of the iPSC clone used for MSC differentiation. b Cell cycle analysis of the lenti-iPSC clone. c Phase-contrast morphology of the BM-MSC,
mRNA-iPSC-MSC-YL001 and the lenti-iPSC-MSC-A001 derived from the lenti-iPSCs. Magnification 200×. d A representative DAPI banded karyotype
result for BM-MSC (P12), mRNA-iPSC-MSC-YL001 (P13) and the lenti-iPSC-MSC-A001 (P10). BM bone marrow, iPSC induced pluripotent stem cell,
MSC mesenchymal stem cell, NHDF normal human dermal fibroblast
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CD90 (Thy-1), and CD105 (endoglin)—and six MSC-
negative surface markers—CD11b (integrin alpha-M),
CD14 (monocyte differentiation antigen), CD31 (platelet
endothelial cell adhesion molecule), CD34 (hematopoietic
progenitor cell antigen), CD45 (T-cell surface glycopro-
tein), and HAL-DR (major histocompatibility complex
class II antigen)—in lenti-iPSC-MSC-A001 (P10), mRNA-
iPSC-MSC-YL001 (P14) and the BM-MSCs (P13) by flow
cytometry. As shown in Fig. 2, the mRNA-iPSC-MSC-
YL001, lenti-iPSC-MSC-A001 and BM-MSCs lacked
expression of CD11b, CD14, CD31, CD34, CD45 and
HLA-DR. Almost 100 % of the lenti-iPSC-MSC-A001 and
mRNA-iPSC-MSC-YL001 cells were positive for CD29,CD44, and CD73, similar to that for BM-MSCs. Robust
expression of CD90 and CD105 (almost 100 % positivity)
was found in BM-MSCs. The abundance of CD90- and
CD105-positive cells in the lenti-iPSC-MSC-A001 cells
was increased following in vitro cultivation. At P3, about
70 % and 80 % of the cells were positive for CD90 and
CD105, respectively (data not shown). At P13, the
lenti-iPSC-MSC-A001 cells were approximately 98.15 %
CD90 positive and 85.64 % CD105 positive (Fig. 2).
Among the mRNA-iPSC-MSC-YL001 cells, robust
CD90 and CD105 expression (89.18 % and 87.47 %
positivity at P14, respectively) were observed, which is
consistent with our previous observation [16]. Thus, it
appears that lenti-iPSC-MSC-A001 (late passage) and
Fig. 2 Flow cytometric analysis of mesenchymal markers CD11b–, CD14–, CD29+, CD31–, CD34–, CD44+, CD45–, CD73+, CD90+, CD105+, and
HLA-DR– in BM-MSCs (P13), mRNA-iPSC-MSC-YL001 (P14), lenti-iPSC-MSC-A001 (P10). Unstained cells were used as flow cytometry control; 10,000
events were recorded for each sample. Bottom panel: percentage of cells positive for each marker is calculated by normalizing to the unstained
cells. A minus value was replaced with “0”. BM bone marrow, iPSC induced pluripotent stem cell, MSC mesenchymal stem cell
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chymal surface marker profiles as BM-MSCs. However,
the MSC surface marker characterization also indicates
the heterogeneity of iPSC-MSCs derived by our
method, with approximately 10 % cells negative for
CD105 (Fig. 2). Based on the finding of passage-
dependent mesenchymal enrichment in the lenti-iPSC-
MSC-A001, cells with over 6 passages were used for the
following functional characterizations.The iPSC-MSCs possess fast proliferative capability
The iPSC-MSCs have become a promising substitute for
BM-MSCs or MSCs derived from other adult tissues.
The advantage of using iPSC-MSCs is attributed to their
higher self-renewal capability. We compared the prolif-
eration rate of the two iPSC-MSC lines to BM-MSCs
using the Click IT-based proliferation assay and flow cy-
tometry. K562 cancer cells were used a positive control
for the assay (55.7 % proliferation rate, Fig. 3a). Higher
Fig. 3 Characterization of cell proliferation and growth. Analysis of the cell proliferation rate with a Click IT cell proliferation assay in a control cell
line (K562, chronic myeloid leukemia-derived cell line), b lenti-iPSC-MSC-YL001 (P7), c mRNA-iPSC-MSC-A001 (P7) and d BM-MSCs (P8). Blue plots
represents negative control without EdU incubation. Pink plots represents cells treated with EdU. e Cumulative population doubling assay of the
BM-MSCs (P11), miPSC-MSC-YL001 (P11) and lenti-iPSC-MSC-A001 (P8) for a period of 2 weeks. BM bone marrow, iPSC induced pluripotent stem
cell, MSC mesenchymal stem cell
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MSC-YL001 (42.2 %, Fig. 3b) and lenti-iPSC-MSC-A001
(39.5 %, Fig. 3c) than the BM-MSCs (27 %, Fig. 3d). The
fast proliferation capacity of iPSC-MSCs was further val-
idated by population doubling array (Fig. 3e).iPSC-MSCs possess adequate osteogenic and
chondrogenic, but less adipogenic capabilities,
compared with BM-MSCs
According to the International Society for Cellular Ther-
apy, the capability of tri-lineage differentiation in vitro is
one of the major criteria for defining MSCs [24]. We
have previously shown that the mRNA-iPSC-MSC-
YL001 line is capable of tri-lineage differentiation, with a
focus on osteogenesis on synthetic biocompatible scaf-
folds [16]. However, the efficacy of tri-lineage differenti-
ation as compared to BM-MSCs is yet to be addressed.
Thus, we compared the osteogenic, chondrogenic andadipogenic differentiation capabilities of the two iPSC-
MSC lines relative to the BM-MSC line.
After 3 weeks of osteogenic induction, calcium
mineralization was observed in all three MSC lines by
Alizarin Red S staining (Fig. 4a). Mineralization was not
observed in the MSCs cultured in normal growth
medium. A more homogeneous and robust calcium stain-
ing was seen in the lenti-iPSC-MSC-A001 than in the
mRNA-iPSC-MSC-YL001. This observation was further
confirmed by quantification of calcium content (Fig. 4b).
The lenti-iPSC-MSC-A001 line has an efficacy of osteo-
genesis similar to BM-MSCs. However, approximately
twofold less osteogenic capacity was found in the mRNA-
iPSC-MSC-YL001 cultures, which is likely due to less
positivity of CD90 (Fig. 2) [25]. Increased expression of
four osteogenic genes (runt-related transcription factor 2
(RUNX2), alkaline phosphatase (ALP), collagen type I
alpha 1 (COL1A1), and osteocalcin (OC)) was detected in
all MSCs after 3 weeks of osteogenic differentiation
Fig. 4 Comparative analyses of the osteogenic capacity of the iPSC-MSCs and BM-MSCs. a Alizarin Red staining of calcium in the BM-MSCs, the
mRNA-iPSC-MSC-YL001, and the lenti-iPSC-MSC-A001 with growth medium or osteogenic medium for 3 weeks. Images are representative of six
repeats. In the left corner there is an image from one well of the 96-well plate. Scale bar for the microscopic images is 300 μm. b Quantitative
calcium deposition of the BM-MSC, mRNA-iPSC-MSC-YL001, and lenti-iPSC-MSC-A001 cells after 3 weeks in the MSC growth medium or osteogenic
medium (n = 8). c Quantitative PCR analysis of the expression of osteogenic genes RUNX2, ALP, COL1A1, and OC in the BM-MSC, mRNA-iPSC-
MSC-YL001, lenti-iPSC-MSC-A001 after 3 weeks in the MSC growth medium or osteogenic medium (n = 6). *P < 0.05. BM bone marrow, iPSC
induced pluripotent stem cell, MSC mesenchymal stem cell
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was more robust in BM-MSCs relative to the iPSC-
MSCs, whereas Col1a1 was more strongly expressed in
the iPSC-MSC cultures. Taken together, these results
suggest that iPSC-MSCs derived with our method can
achieve an adequate osteogenic efficacy similar to that
of BM-MSCs.For chondrogenic differentiation, the lenti-iPSC-MSC-
A001, mRNA-iPSC-MSC-YL001 and BM-MSC lines were
grown in a “V” shape 96-well plate according to a protocol
described previously [26]. Toluidine blue staining of pellet
sections was used to assess chondrogenic differentiation.
Cartilaginous extracellular matrix is stained purple while
undifferentiated or fibrous tissue is stained blue. After
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extracellular matrix was detected in all MSC lines cultured
in chondrogenic medium (Fig. 5d–f ), but not in growth
medium (Fig. 5a–c). The lenti-iPSC-MSC-A001 and
mRNA-iPSC-MSC-YL001 had formed similar cartilagin-
ous structures compared with the BM-MSCs.Fig. 5 Comparative analysis of the chondrogenic and adipogenic capacitie
BM-MSCs (a and d), the mRNA-iPSC-MSC-YL001 (b and e), and the lenti-iPS
chondrogenic medium (d–f). Oil-Red O staining of lipids in the BM-MSCs (g a
(i and l) after 3 weeks in MSC growth medium (g–i) or adipogenic medium (j
lipids (j–l). Scale bar: a–f, 150 μm; g–l, 300 μmThe adipogenic potential of the iPSC-MSCs was also
characterized by in vitro adipogenic differentiation. Lipid
droplets formed by adipogenesis were assessed by Oil
Red O staining. After 3 weeks of adipogenic differenti-
ation, lipid droplets were formed in both iPSC-MSC
lines and the BM-MSCs in the adipogenic differentiations. Toluidine blue staining of cartilaginous extracellular matrix of the
C-MSC-A001 (c and f) after 3 weeks in MSC growth medium (a–c) or
nd j), the mRNA-iPSC-MSC-YL001 (h and k), and the lenti-iPSC-MSC-A001
–l). Arrow heads indicate the cartilaginous extracellular matrix (d–f) and
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(Fig. 5g–i). However, the adipogenic efficacy of both
iPSC-MSC lines was much lower than the BM-MSCs.
Lipid droplets from iPSC-MSCs were much smaller than
those from BM-MSCs.
The iPSC-MSCs and tri-lineage differentiated cells lack
expression of stemness genes
Loss of “stemness” in iPSC-MSCs and iPSC-MSC-
derived lineages is one crucial safety criterion when ap-
plying iPSC-MSCs to tissue engineering and cell therapy.
Lack of tumorigenic potential of the mRNA-iPSC-MSC-
YL001 line was validated previously [16]. We further
characterized the loss of “stemness” in the iPSC-MSC
lines by analyzing the expression of 11 stemness genes
(OCT4, KLF4, C-MYC, SOX2, GDF3, CRIPTO, UTF1,
DPPA4, DNMT3B, LIN28A and SALL4) in the original
iPSCs, iPSC-MSCs, and tri-lineage differentiated cellsFig. 6 Gene expression analysis of “stemness” genes in the NHDFs, iPSCs (t
lenti-iPSC-MSC-A001 and the three derived lineages (osteogenic, chondrog
homeobox 1 (OCT4/ POU5F1), Kruppel-like factor 4 (KLF4), v-myc avian mye
region Y)-box 2 (SOX2), growth differentiation factor 3 (GDF3), teratocarcinom
cell transcription factor 1 (UTF1), developmental pluripotency associated 4 (DP
homolog A (LIN28A) and spalt-like transcription factor 4 (SALL4)) was analyzed
chondrogenic and adipogenic medium; b NHDF, mRNA-iPSCs, mRNA-iPSC-M
in osteogenic, chondrogenic and adipogenic medium; c NHDF, lenti-iPSCs, len
in osteogenic, chondrogenic and adipogenic medium. BM bone marrow, iPSC
human dermal fibroblast(osteogenesis, chondrogenesis, and adipogenesis). All
stemness genes were expressed in the iPSCs, whereas
most stemness genes, except Klf4 and C-Myc, were
not expressed in the iPSC-MSCs and the tri-lineage
differentiated cells (Fig. 6). We also found that Klf4
and c-Myc were expressed in the NHDF, which is simi-
lar to what has been reported previously [8, 27].
Discussion
With technical improvements in generating pluripotent
stem cells, differentiation of iPSCs to functionally spe-
cific cell types remains a major challenge. MSCs are a
promising cell type for personalized therapies such as
tissue engineering [28], immunosuppressive biotherapy
[29], and regenerative organ repair [30]. We have previ-
ously developed a simple protocol to derive iPSC-MSCs
and applied them for bone tissue engineering in syn-
thetic three-dimensional scaffolds and nanofibers [4, 16].wo lines: mRNA-iPSC and lenti-iPSC), BM-MSCs, mRNA-iPSC-MSC-YL001,
enic, adipogenic). Expression of eleven stemness genes (POU class 5
locytomatosis viral oncogene homolog (C-MYC), SRY (sex determining
a-derived growth factor 1 (CRIPTO/ TDGF1), undifferentiated embryonic
PA4), DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B), lin-28
by PCR. a BM-MSCs in growth medium, and after 3 weeks in osteogenic,
SC-YL001 in growth medium, and mRNA-iPSC-MSC-YL001 after 3 weeks
ti-iPSC-MSC-A001 in growth medium, and lviPSC-MSC-A001 after 3 weeks
induced pluripotent stem cell, MSC mesenchymal stem cell, NHDF normal
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our protocol) to naïve BM-MSCs. This study demon-
strated that the iPSC-MSCs derived by our protocol
display many similar characteristics relative to the BM-
MSCs, including fibroblast-like morphology, expression
of typical mesenchymal markers, the capacity to effi-
ciently differentiate into osteogenic and chondrogenic
lineages, and loss of pluripotency. This study further
supports our previous finding of efficient osteogenic
potential for iPSC-MSCs in three-dimensional scaffolds
and nanofibers [4, 16].
There are several advantages of using iPSC-MSCs for
MSC-based therapies as compared to primary MSCs.
The high proliferative capability iPSC-MSCs proven by
this study (Fig. 3) and others [31–33], as well as the in-
finite self-renewal capacity of iPSCs [8], increase the
potential of MSC-based cell therapies, which commonly
requires repetitive administration of a large number of
MSCs. Although MSCs can be easily isolated from
various sources of adult tissues, such as BM, fat, pla-
centa, blood, spleen, heart, pancreas, joints and so
forth [34–36], this repetitive MSC isolation procedure
would cause pain and risk of infection for patients.
Furthermore, for certain patients with inherited gen-
etic problems or age-related disorders, iPSC-MSCs
would represent the best solution for gene- and cell-based
therapy. One such example is Osteogenesis imperfect
(OI), which is caused by dominant mutations of the
type one collagen genes. With an adeno-associated
virus-mediated gene targeting strategy, Deyle et al. gen-
erated iPSC-MSCs derived from OI patients and subse-
quently inactivated the mutated COL1A1 and COL1A2
genes in the iPSC-MSCs. The targeted iPSC-MSCs
were able to restore normal collagen production and
bone formation [37].
In terms of osteogenic and chondrogenic capacities of
the iPSC-MSCs, we now have further confirmed their
adequate efficacy relative to BM-MSCs [4, 16]. Although
only the osteogenicity was thoroughly investigated in
this study due to our research focus, the chondrogenicity
of iPSC-MSCs has been systematically confirmed by
studies from other research groups [38, 39].
However, this study also showed that both iPSC-MSC
lines were less efficient with respect to adipogenic differ-
entiation relative to their osteogenicity and chondrogeni-
city (Fig. 5). Although both iPSC-MSC lines derived by
our protocol were capable of adipogenesis [16], the
adipocytes and lipid droplets were much smaller in the
cultures of iPSC-MSCs compared with those of BM-
MSCs. Similarly, iPSC-MSCs derived by other methods
have been reported to have less adipogenicity than BM-
MSCs [32, 40]. A similar observation was reported for
MSCs derived from human ESCs [41]. It is still unknown
why MSCs derived from iPSCs or ESCs show lesscommitment towards adipogenicity. Many intrinsic fac-
tors could affect the adipogenicity of iPSC-MSCs, such
as the iPSC-MSC derivation and cultivation methods,
iPSC-MSC purity, and tissue of origin. Hynes et al. re-
cently compared iPSC-MSCs originating from three dif-
ferent tissues: gingiva, periodontal ligament, and lung
[42]. Although the efficacy of adipogenesis of those
iPSC-MSCs was not assessed in their study, various cap-
acities were observed among the three iPSC-MSCs lines,
suggesting the notion that the tissue of origin plays a vital
role in commitment differentiation. In our study, the
lenti-iPSC-MSC-A001 had a higher adipogenic capacity
than the mRNA-iPSC-MSC-YL001. However, both iPSC-
MSCs lines were derived from dermal fibroblasts. Thus,
the adipogenic difference may be due to clonal variation,
which has been reported in other studies [42, 43].
According to ClinicalTrail.gov to date, there are 452
studies registered for “mesenchymal stem cells”, 32 stud-
ies registered for “induced pluripotent stem cells”, and
27 studies registered for both “mesenchymal stem cells”
AND “induced pluripotent stem cells”. One key concern
when using iPSCs and MSCs derived from iPSCs for cell
therapy is their potential for teratoma formation. We
have shown that the iPSC-MSCs generated by our
method do not form teratoma after transplanting into
immune deficient mice [16]. In this study, we further
characterized a few “stemness” genes in the iPSC-MSCs.
Except for KLF4 and C-MYC, the rest of the “stemness”
genes (OCT4, SOX2, GDF3, CRIPTO, UTF1, DPPA4,
DNMT3B, LIN28A, SALL4) were not expressed in the
iPSC-MSC lines, further implicating the safety aspect of
the iPSC-MSCs. KLF4 and C-MYC were also expressed
in the BM-MSCs and in primary fibroblasts. Similarly,
KLF4 and C-MYC were reported to be expressed in
human fibroblasts by a previous study [8], suggesting
that the presence of KLF4 and C-MYC should not con-
tribute to teratoma formation by the iPSC-MSCs. With
more studies conducted to characterize the safety and
efficacy aspects of iPSC-MSCs, increasing numbers of
clinical trials using iPSC-MSCs are expected in the
future. We also observed an expression difference for
KLF4 and C-MYC between the mRNA-iPSC-MSC-
YL001 and lenti-iPSC-MSC-A001 after osteogenic and
adipogenic differentiation. Since KLF4 and C-MYC are
expressed in mRNA-iPSC-MSC-YL001 and lenti-iPSC-
MSC-A001 cells, the expression of KLF4 and C-MYC in
osteogenic and adipogenic samples might have resulted
from the proportion of parental iPSC-MSCs that failed
to differentiate. The difference between the two iPSC-
MSC lines could have resulted from the different mesen-
chymal heterogeneity of these two iPSC-MSCs as shown
in Fig. 2.
Another important challenge for generating clinically
compliant iPSC-MSCs is the time-effective generation of a
Kang et al. Stem Cell Research & Therapy  (2015) 6:144 Page 13 of 14large amount of functional MSCs. Several methods have
been described to derive functional MSCs from human
iPSCs. These methods vary from each other in terms of
ingtermediate embryoid bodies, surface coating of tissue
culture vessels, differentiation medium, and supple-
ment of pathway inhibitors (e.g., the p38 MAPK inhibi-
tor, SB203580 and the transforming growth factor-β
pathway inhibitor SB431542) [32, 44]. The use of mol-
ecule SB431542 did not improve the adipogenic cap-
acity of iPSC-MSCs [32]. However, robust adipogenesis
of iPSC-MSCs has been achieved by supplementing the
SB203580 inhibitor [44]. Our method for iPSC-MSC
derivation involves neither intermediate embryoid bod-
ies nor the use of pathway inhibitors. The derivation of
iPSC-MSCs is achieved by MSC medium-mediated
pre-differentiation, followed by MSC enrichment by
serial passaging in MSC culture condition, which take
approximately 1 month [4, 16]. A similar method has
been applied to derive functional MSCs by other groups
[42, 45]. Compared to the embryoid body-based differenti-
ation method, this method is more time- and cost-
effective, and compliant with large-scale production. How-
ever, as proved in this study, further improvements are
still required for our iPSC-MSC method to generate func-
tional MSCs that can resemble the naïve BM-MSC
functions.Conclusions
The iPSC-MSCs derived by our method display most
mesenchymal characteristics similar to adult BM-MSCs.
The iPSC-MSCs achieve robust osteogenicity and chon-
drogenicity, but have very limited adipogenicity. Our
results suggest that these iPSC-MSCs present a promis-
ing alternative cell source for MSC-based therapeutic
applications.
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